



CLL FISH

Targeted Detection of CLL-Associated Chromosomal Abnormalities

CLL FISH uses fluorescence in situ hybridization to detect recurrent chromosomal abnormalities associated with Chronic Lymphocytic Leukemia (CLL). The panel evaluates clinically relevant genetic changes that can provide important information for disease characterization, prognosis, and patient management.

Why Order CLL FISH?

- Detects common chromosomal abnormalities associated with CLL
- Identifies abnormalities that may not be detected by conventional chromosome analysis
- Does not require dividing cells
- Provides targeted evaluation of clinically relevant CLL-associated loci
- Useful when metaphase cells are limited or unavailable
- Supports disease characterization and risk assessment

Clinical Applications:

- Evaluation of patients with newly diagnosed CLL
- Cytogenetic characterization of CLL
- Identification of clinically relevant chromosomal abnormalities
- Complementary testing alongside flow cytometry, cytogenetics, and molecular assays

Why EmeritusDX?

- Comprehensive hematologic diagnostic services
- Integrated FISH, Flow Cytometry, Molecular, Cytogenetic, and Hematopathology testing
- Expert interpretation by board-certified hematopathologists
- TAT: 3-5 Days
- CAP-Accredited
- CLIA-Certified

Panel Targets:

6q23 (MYB) 11q22 (ATM) t(11;14) (CCND1/IGH) Cen 12 13q14 (MYB, DLEU) 17p13 (TP53)

